Key statistics
On Tuesday, Abivax SA (2X1:STU) closed at 100.60, -23.32% below its 52-week high of 131.20, set on Jan 12, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 99.30 |
|---|---|
| High | 101.40 |
| Low | 97.70 |
| Bid | 100.40 |
| Offer | 101.00 |
| Previous close | 99.30 |
| Average volume | 380.90 |
|---|---|
| Shares outstanding | 79.07m |
| Free float | 72.76m |
| P/E (TTM) | -- |
| Market cap | 7.76bn EUR |
| EPS (TTM) | -3.09 EUR |
Data delayed at least 15 minutes, as of Feb 10 2026.
More ▼
Announcements
- Abivax to be Added to Nasdaq Biotechnology Index
- Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
- Abivax Presents First Half 2025 Financial Results
- Abivax Announces Closing of $747.5 Million Public Offering
- Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
- Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
- Abivax announces trading resumption of its ordinary shares on Euronext Paris
- Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
- Abivax Presents First Quarter 2025 Financial Results
- Abivax publishes financial reports with the French and U.S. securities regulatory agencies
More ▼
